Drugs / remogliflozin etabonate
remogliflozin etabonate
also known as
GSK189075 · BHV-091009 · Etabonate de remogliflozine · Etabonato de remogliflozina · GSK189075A
Small molecule targets SLC5A2 via inhibition
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT00671424 | Mar → May 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00625859 | Jan → Apr 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00559884 | Nov 2007 → ? | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00519480 | Sep 2007 → Apr 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00532610 | Sep 2007 → Feb 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00501462 | Jul 2007 → Mar 2008 | impaired renal function disease, type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00501930 | Apr 2007 → ? | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00504816 | Apr 2007 → Jan 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00501397 | Feb 2007 → ? | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00501683 | Nov 2006 → ? | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00494767 | Sep 2006 → Jun 2007 | obesity disorder, type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00376038 | Aug → Oct 2006 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01571661 | Sep 2004 → Jan 2005 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02537470 | Jul 2015 → Aug 2016 | type 2 diabetes mellitus | BHV Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00575159 | Mar → Dec 2008 | type 1 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00495469 | Aug 2007 → Jun 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00500331 | Jan 2007 → Feb 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00291356 | Jan → May 2006 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Remogliflozin etabonate | “Assessment of safety and tolerability of remogliflozin etabonate (GSK189075)” PMID 34120651 ↗ Jun 2021 |
| Known as | BHV-091009 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2028665 ↗ |
| Known as | Etabonate de remogliflozine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2028665 ↗ |
| Known as | Etabonato de remogliflozina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2028665 ↗ |
| Known as | GSK189075 | “Assessment of safety and tolerability of remogliflozin etabonate (GSK189075)” PMID 34120651 ↗ Jun 2021 |
| Known as | GSK189075A | “GSK189075A 20mg” NCT01571661 ↗ |
| Action | Inhibit | “remogliflozinetabonate, an SGLT2 inhibitor” PMID 34120651 ↗ Jun 20211“Sodium/glucose cotransporter 2 inhibitor” CHEMBL2028665 ↗ |
| Modality | Small molecule | — CHEMBL2028665 ↗ |
| Route | Oral | “GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth” NCT00291356 ↗ |
| Target | SLC5A2 | “Sodium/glucose cotransporter 2 inhibitor” CHEMBL2028665 ↗ |